Reply to K. P. Dieckmann

Affiliations

¹ Michael Schaapveld, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands and Joost M. Blok, MD, University Medical Center Utrecht, Utrecht, the Netherlands.

Comment

Michael Schaapveld et al. J Clin Oncol. 2021.

. 2021 May 20;39(15):1690.

doi: 10.1200/JCO.21.00209. Epub 2021 Mar 16.

¹ Michael Schaapveld, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands and Joost M. Blok, MD, University Medical Center Utrecht, Utrecht, the Netherlands.

No abstract available

Comment on

Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer.
Blok JM, Groot HJ, Huele EH, de Wit R, Horenblas S, Nuver J, Groenewegen G, Bosch JLHR, Witjes JA, Tromp JM, de Brouwer PJM, van den Berg HA, Vanneste BGL, Smilde TJ, Aarts MJB, Gietema JA, Meijer RP, Schaapveld M. Blok JM, et al. J Clin Oncol. 2021 Feb 1;39(4):319-327. doi: 10.1200/JCO.20.02352. Epub 2020 Oct 29. J Clin Oncol. 2021. PMID: 33119475
Does Testicular Seminoma Involve a Higher Predisposition Than Nonseminoma to Develop Contralateral Testicular Tumors?
Dieckmann KP. Dieckmann KP. J Clin Oncol. 2021 May 20;39(15):1689-1690. doi: 10.1200/JCO.20.03236. Epub 2021 Mar 16. J Clin Oncol. 2021. PMID: 33724872 No abstract available.